Anti-DNA Antibody Production by CD5+ and CD5− B Cells of Patients with Systemic Lupus Erythematosus

Noboru Suzuki, Tsuyoshi Sakane,* and Edgar G. Engleman
Department of Pathology, Stanford University, Stanford, California 94305; and *Department of Internal Medicine, Shimane Medical University, Izumo, Shimane 693, Japan

Abstract

Although the presence of anti-DNA antibody is a hallmark of systemic lupus erythematosus (SLE), neither the subsets of B cells that secrete anti-DNA antibody nor the stimuli responsible for the induction of anti-DNA secretion is known. In particular, the role of CD5+ B cells in human SLE, a distinct subpopulation of antibody-secreting cells that previously has been identified as a source of anti-DNA antibody in murine SLE, is unknown. To approach these questions, we developed a sensitive enzyme-linked immunospot (ELISpot) assay to measure spontaneous secretion of antibody to single-stranded (ss) DNA, double-stranded (ds) DNA, tetanus toxoid, and polyclonal immunoglobulin (Ig) by purified CD5+ and CD5− B cells of 15 SLE patients and 15 healthy control subjects. The B cells of only 1 of 15 healthy subjects secreted a significant level of anti-ssDNA antibody, and none secreted anti-dsDNA. By contrast, in the majority of SLE patients both CD5+ and CD5− B cells secreted IgG and/or IgM anti-ssDNA as well as anti-dsDNA antibody. Further analysis of the anti-ssDNA response revealed that the level of IgG and IgM anti-DNA antibody secretion by CD5− B cells correlated closely with the level of polyclonal Ig production by the same subpopulation (r = 0.81 and 0.70, respectively). In contrast, production of anti-DNA by CD5+ B cells occurred independently of polyclonal Ig production by both CD5+ and CD5− B cell subpopulations. These results suggest that in human SLE there exist two anti-DNA antibody-producing B cell subpopulations with distinct induction mechanisms: one (CD5+), which independently secretes anti-DNA, and another (CD5−), which produces anti-DNA as an apparent consequence of polyclonal B cell activation. (J. Clin. Invest. 1990. 85:238–247.) anti-DNA antibody • CD5+ B cells • CD5− B cells • polyclonal B cell activation • systemic lupus erythematosus

Introduction

Systemic lupus erythematosus (SLE) is a multisystem disease of unknown etiology characterized by aberrant immune regulation and excessive production of multiple autoantibodies (1–8). In spite of extensive studies of both SLE patients and mouse models of lupus-like disease, considerable controversy remains as to whether excess autoantibody production reflects specific stimulation of autoreactive clones (as in a response to a specific and/or cross-reactive antigen) (3, 9) or polyclonal activation of many different B cells (10–12). The model of selective B cell activation is supported by several findings: (a) there is a disproportionate increase in the concentration of antibodies to a few selected autoantigens in the sera of most autoimmune patients and mice (13, 14); (b) B cells capable of autoantibody production selectively and rapidly expand when transferred from autoimmune mice to B cell-depleted recipient mice (15); and (c) most of the antibody responses in a chronic graft-versus-host F1 model of SLE are not random but, rather, specific to the autoantigens present at the initiation of the disease (16). However, numerous lines of evidence also support an etiologic role for polyclonal B cell activation in SLE. For example, (a) B cell hyperresponsiveness and spontaneous polyclonal activation are invariably present in both SLE patients and animal models of SLE (1, 19–21); (b) activation of B cells, in vitro or in vivo, with polyclonal stimulators results in production of a variety of autoantibodies similar to those found in SLE (22, 23); (c) chronic polyclonal activation in genetically nonautoimmune mice can cause autoimmune disease (24); and (d) genetic studies indicate an intrinsic B cell abnormality in several autoimmune strains of mice that is linked to polyclonal B cell hyperactivity (1, 25).

The recent discovery that most autoantibodies produced by mice with genetically determined autoimmune disease are derived from B cells expressing the CD5 (Ly1) antigen (17, 18) offers an exciting new avenue for investigation into the pathogenesis of human autoimmune disease. CD5+ B cells have been found in high numbers in fetal spleen, chronic lymphocytic leukemia, recipients of bone marrow allografts, and patients with rheumatoid arthritis. A variety of studies suggest that human CD5+ B cells constitute a distinct B cell lineage, homologous functionally and phenotypically to mouse Ly1+ B cells (26–34). Moreover, upon in vitro stimulation with polyclonal activators, CD5+ B cells produce autoantibodies similar to those seen in rheumatoid arthritis and SLE (27, 28).

Despite these provocative findings, a role for CD5+ B cells in the production of anti-DNA antibody in SLE has not yet been demonstrated. In an effort to explore this question, we used a sensitive assay to measure the spontaneous production of anti-DNA antibody by CD5+ and CD5− B cells obtained from patients with SLE. The results indicate that both CD5+ and CD5− B cells produce anti-DNA antibody. However, CD5− B cells appear to produce anti-DNA as a consequence of polyclonal activation, in vivo, whereas CD5+ B cells do not.

Methods

Patient selection. We studied 15 patients, all women, who fulfilled American Rheumatism Association criteria for the diagnosis of SLE.
(35). The mean age (±SD) of these patients was 33.7±10.7 yr (range 19–56 yr) (Table I). Disease activity was assessed at the time of phlebotomy on the basis of clinical and laboratory findings (fever, arthralgias, rash, oral ulcers or alopecia, elevated erythrocyte sedimentation rate (>30 mm/h), leukopenia (<4.000/μl), hypoalbuminemia (<3.5 g/dl), hypocomplementemia (CH50 <20 U/ml), and presence of anti-nuclear antibody (titer >1:80) (36). Seven patients with three or more of these criteria were categorized as active; eight patients with two or fewer criteria of activity were included in the inactive group. At the time of study seven patients were receiving no treatment, five were receiving low-dose corticosteroid therapy (prednisone 5–10 mg/d), two patients were receiving intermediate-dose prednisone (15 mg/d), and one patient was on high-dose prednisone (40 mg/d) (Table I). One patient had received total lymphoid irradiation 3 yr before the study. No patients were receiving cytotoxic drugs at the time of study.

15 healthy volunteer blood donors (12 women and 3 men) served as control subjects. Their mean age (±SD) was 37.7±11.8 yr (range 23–61 yr).

Cell separation. Peripheral blood mononuclear cells were separated into T and non-T enriched fractions with a sheep erythrocyte rosetting technique (36). Monocytes were depleted from the non-T cell fraction by adherence on plastic petri dishes (37, 38). The remaining non-T, nonadherent cells were enumerated by flow cytometry (CD5+ B cells CD5- B cells CD5+ B cells CD5- B cells CD5+ B cells CD5- B cells) (Table I). One patient had received total lymphoid irradiation 3 yr before the study. No patients were receiving cytotoxic drugs at the time of study.

Table I. Patient Profile and Spontaneous Antibody Production

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age</th>
<th>Disease activity</th>
<th>Disease duration</th>
<th>Drug dose</th>
<th>Total IgM production</th>
<th>Total IgG production</th>
<th>IgM anti-ssDNA production</th>
<th>IgG anti-ssDNA production</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CDS5+ B cells CDS5- B cells</td>
<td>CDS5+ B cells CDS5- B cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>42</td>
<td>Inactive</td>
<td>12 yr</td>
<td>PSN 5</td>
<td>5,200</td>
<td>2,500</td>
<td>5,500</td>
<td>17,500</td>
</tr>
<tr>
<td>2</td>
<td>25</td>
<td>Active</td>
<td>7 yr</td>
<td>None</td>
<td>2,000</td>
<td>1,800</td>
<td>5,400</td>
<td>23,000</td>
</tr>
<tr>
<td>3</td>
<td>30</td>
<td>Inactive</td>
<td>3 yr</td>
<td>PSN 10</td>
<td>1,100</td>
<td>900</td>
<td>1,200</td>
<td>1,300</td>
</tr>
<tr>
<td>4</td>
<td>26</td>
<td>Active</td>
<td>3 yr</td>
<td>PSN 15</td>
<td>5,400</td>
<td>7,900</td>
<td>4,050</td>
<td>4,100</td>
</tr>
<tr>
<td>5</td>
<td>45</td>
<td>Inactive</td>
<td>10 yr</td>
<td>None</td>
<td>5,000</td>
<td>2,167</td>
<td>6,400</td>
<td>3,300</td>
</tr>
<tr>
<td>6</td>
<td>46</td>
<td>Active</td>
<td>7 yr</td>
<td>None</td>
<td>4,400</td>
<td>2,467</td>
<td>21,800</td>
<td>8,900</td>
</tr>
<tr>
<td>7</td>
<td>24</td>
<td>Active</td>
<td>2 yr</td>
<td>None</td>
<td>17,200</td>
<td>3,469</td>
<td>18,500</td>
<td>5,000</td>
</tr>
<tr>
<td>8</td>
<td>25</td>
<td>Active</td>
<td>5 yr</td>
<td>PSN 10</td>
<td>6,200</td>
<td>4,700</td>
<td>16,600</td>
<td>16,600</td>
</tr>
<tr>
<td>9</td>
<td>19</td>
<td>Active</td>
<td>1 wk</td>
<td>None</td>
<td>7,000</td>
<td>3,500</td>
<td>3,500</td>
<td>4,500</td>
</tr>
<tr>
<td>10</td>
<td>24</td>
<td>Inactive</td>
<td>3 yr</td>
<td>PSN 10</td>
<td>5,500</td>
<td>1,000</td>
<td>23,000</td>
<td>2,000</td>
</tr>
<tr>
<td>11</td>
<td>28</td>
<td>Active</td>
<td>1 wk</td>
<td>None</td>
<td>11,500</td>
<td>11,500</td>
<td>23,000</td>
<td>20,000</td>
</tr>
<tr>
<td>12</td>
<td>30</td>
<td>Inactive</td>
<td>4 yr</td>
<td>None</td>
<td>1,550</td>
<td>6,500</td>
<td>2,500</td>
<td>1,500</td>
</tr>
<tr>
<td>13</td>
<td>46</td>
<td>Inactive</td>
<td>10 yr</td>
<td>PSN 10</td>
<td>2,850</td>
<td>7,250</td>
<td>4,700</td>
<td>17,000</td>
</tr>
<tr>
<td>14</td>
<td>40</td>
<td>Active</td>
<td>1 wk</td>
<td>None</td>
<td>6,250</td>
<td>10,000</td>
<td>4,500</td>
<td>18,000</td>
</tr>
<tr>
<td>15</td>
<td>56</td>
<td>Inactive</td>
<td>20 yr</td>
<td>PSN 15</td>
<td>4,000</td>
<td>4,950</td>
<td>4,800</td>
<td>3,000</td>
</tr>
</tbody>
</table>

* Disease activity was assessed at the time of phlebotomy by the criterion described in Methods. † Spontaneous antibody production was measured by ELISPOT assay described in Methods. Each value represents the mean number of spots/106 B cells tested. ‡ NS, anti-ssDNA < mean + 2 SD of 15 normal controls: IgM anti-ssDNA from CDS5+ B cells, those from CDS5- B cells, IgG anti-ssDNA from CDS5+ B cells and those from CDS5- B cells were <25, <35, <23, and <30, respectively. § PSN, prednisone.
Preparation of antigen-coated plates. For measurement of anti-DNA antibody, 100 μg/ml of ssDNA or dsDNA was added to 96-well microtiter plates (Immulon 1; Dynatech, Alexandria, VA) which were precoated with 0.01% methylated BSA (Sigma) and incubated overnight at 4°C. To measure anti-tetanus toxoid (TT) antibody, 5 limes flocculation U/ml of tetanus toxoid (Massachusetts State Department of Public Health, Jamaica Plain, MA) was dissolved in carbonate buffer and coated onto 96-well microtiter plates. In order to estimate total (polyclonal) Ig production, goat anti-human IgM or IgG (Cappel Laboratories, West Chester, PA) (10 μg/ml) was coated onto the plates.

ELISPOT assays. Highly enriched B cell subpopulations or mitogen activated peripheral blood lymphocytes were suspended in DMEM supplemented with 3% BSA (R1A grade, Sigma). Serial dilutions of these cell suspensions, usually starting with 2.5 × 10^6 cells/well for freshly isolated B cell subpopulations, 2 × 10^5 cells/well for SAC I stimulated B cells, and 2 × 10^6 cells/well for mitogen activated PBL, were incubated on antigen coated plates for 12–18 h at 37°C in an atmosphere of 5% CO_2 in air. As a control, cells were also incubated on plates uncoated with antigen or anti-Ig. Thereafter, the cells were removed with PBS/0.05% Tween 20 and distilled water, and the plates were overlaid with biotin conjugated anti-human IgM or IgG (Kirkegaard and Perry Laboratories, Gaithersburg, MD) for overnight incubation at 4°C. The plates were washed again and streptavidin-alkaline phosphatase (Bethesda Research Laboratories, Gaithersburg, MD) was added and the plates incubated for 1 h at room temperature. Antibodies produced by individual B cells that bound to the plate were visualized by addition of a solution of 5-bromo-3-chloroindolyl phosphate (Sigma) in a low gelling temperature agarose kept at 44°C. Alkaline phosphatase acts on this substrate to produce a blue spot that cannot diffuse through the agarose once it solidifies at room temperature (42–45). To calculate the number of antigen-specific spots, the number of spots on antigen uncoated control wells were subtracted from the number on antigen-coated wells.

Statistical methods. Statistical significance was ascertained by the Student's t test and linear regression analysis. Probability values of > 5% were considered not significant.

Results

Characterization of the ELISPOT assay. Attempts to apply conventional anti-DNA ELISA (46) for measurement of spontaneous anti-DNA secretion were unsatisfactory due to inadequate sensitivity (data not shown). Therefore, we adapted the ELISPOT technique, which detects individual antibody secreting cells rather than secreted antibody. The sensitivity and specificity of this assay have been documented in murine (42, 43) as well as human (44, 45) systems, and further characterized and confirmed for the antigens studied herein. If antigen or anti-Ig antibody was not coated onto the plate, spots (indicating antibody secretion) did not develop even in the presence of B cells (data not shown). In the presence of antigen, the ELISPOT assay was highly specific as shown in competitive inhibition experiments (Fig. 1). For determination of isotype specificity, normal PBL activated for 6 d with PWM were incubated for 12 h on plates coated with anti-human IgM or anti-human IgG antibody. As an inhibitor, chromatography purified human IgG or IgM (myeloma derived; Jackson Immunoresearch Laboratories, Avondale, PA) was added to the well at a
concentration of 0.01-100 μg/ml. The anti-IgM ELIspot was unaffected by IgG but was inhibited by IgM in a dose-dependent manner (Fig. 1 a). Conversely, development of the anti-IgG ELIspot was specifically blocked by IgG but not IgM (Fig. 1 b).

We next examined the antigen specificity of IgM anti-DNA and IgM anti-tetanus toxoid (TT) ELIspot assays using SAC I and PWM-activated normal PBL as indicator cells and ssDNA, TT, and human IgG as inhibitors. As shown in Fig. 1, c and d, the anti-ssDNA and anti-TT ELIspot assays were inhibited, respectively, by ssDNA and TT in a dose-dependent fashion, but not by irrelevant antigens. Similarly, using SLE PBL and normal PBL, the specificity of IgG anti-DNA and IgG anti-TT ELIspot assays was confirmed (data not shown).

Spontaneous production of polyclonal immunoglobulin from SLE CD5+ and CD5− B cells. To determine whether CD5+ and/or CD5− B cells were responsible for the excessive production of polyclonal Ig in SLE (19–21), freshly isolated B cell subpopulations of SLE patients were cultured on anti-human IgM or IgG coated plates for 18 h, and the number of Ig producing cells was determined by ELIspot assay (Table I and Fig. 2). Among healthy subjects, relatively low numbers of CD5− B cells spontaneously secreted IgM or IgG (spontaneous Ig producing cells/10⁶ B cells [mean±SE]; IgM, 1,278±214; IgG, 1,028±274) (Fig. 2). Somewhat higher numbers of CD5− B cells from the same normal subjects produced IgM and IgG (IgM, 2,750±396; IgG, 3,249±412). A higher proportion of CD5+ and CD5− B cells of SLE patients spontaneously secreted both IgM and IgG than did normal controls (SLE CD5+ B cells: IgM, 5,677±1,019; IgG, 9,767±2,076; SLE CD5− B cells: IgM, 4,707±817; IgG, 9,680±1,984). These results suggest that both CD5+ and CD5− B cells are activated in vivo in SLE patients.

Spontaneous production of anti-DNA antibody by SLE CD5+ and CD5− B cells. We next examined the CD5+ and CD5− B cells from our SLE and healthy control cohorts for their spontaneous secretion of anti-ssDNA antibody. In order to obtain information about the cellular source of antibodies to a nominal foreign antigen, we simultaneously measured the spontaneous production of anti-TT antibody by these B cell subpopulations. As shown in Fig. 3, a and b, B cells from the majority of SLE patients secreted anti-ssDNA, whereas only a single healthy control subject had detectable anti-ssDNA secreting cells. The CD5− B cells from 6 of the 15 SLE patients studied secreted IgM anti-ssDNA antibody at levels significantly greater (> 2 SD) than background. The CD5− B cells from nine patients secreted significant levels of IgG anti-ssDNA. A similar number of patients (seven for both IgM and IgG anti-ssDNA antibody) had circulating CD5+ B cells which spontaneously secreted anti-ssDNA antibody. In addition, those that did so had roughly equivalent numbers of anti-ssDNA secreting CD5+ and CD5− B cells. Although the results shown in Table I and Fig. 3 were obtained with B cell subpopulations isolated by panning, virtually identical results were obtained in a study of CD5+ and CD5− subsets isolated to > 98% purity with a fluorescence activated cell sorter, confirming that anti-ssDNA antibody is secreted by both B cell subpopulations (data not shown). In addition, we restained each B cell subpopulation after 6 d stimulation with SAC I and confirmed that their phenotypes corresponded to those originally selected (see below).

In addition to the studies of anti-single stranded (ss) DNA antibody production, in six patients we also studied spontaneous anti-double stranded (ds) DNA antibody production. As shown in Fig. 4, the CD5− B cells from all six patients spontaneously secreted IgG anti-dsDNA. In four of these patients both the CD5+ and CD5− B cells produced IgG as well as IgG anti-dsDNA antibody. As shown in the same figure, the CD5+ and CD5− B cells from healthy subjects did not secrete any detectable anti-dsDNA antibody. The possibility exists that some of the dsDNA denatured upon fixation to the ELISA plates and what appears as anti-dsDNA antibody, in fact, represents anti-ssDNA antibody. However, addition of dsDNA to the anti-dsDNA ELIspot assay inhibited the assay, whereas ssDNA did not (data not shown), confirming the specificity of the assay. On this basis, we conclude that CD5+ and CD5− B cells from SLE patients secrete anti-dsDNA as well as anti-ssDNA antibodies.

In results similar to those for anti-DNA secreting cells, the majority of SLE patients had circulating B cells that spontaneously secreted antibody to TT, whereas normal subjects did not (Fig. 3, c and d). However, in contrast to anti-DNA, anti-TT antibody was produced almost exclusively by CD5− B cells from these patients, and consisted almost entirely of immunoglobulin of IgM isotype. The absolute number of IgM anti-TT antibody secreting CD5− cells was slightly lower than that of IgM anti-ssDNA antibody secreting CD5− cells from the same patients (60.9±31.3 vs. 113.4±58.6/10⁶ B cells).

To determine whether a disproportionate percentage of B cells from SLE patients secreted anti-DNA or anti-TT antibody, we evaluated specific antibody production as a percentage of total Ig secretion. As shown in Fig. 5, the number of IgM anti-ssDNA antibody secreting cells constituted a mean of 1.6% and 1.8% of total IgM secreting cells in CD5+ and CD5− B cell subsets, respectively. IgG anti-ssDNA antibody secreting cells constituted 0.6% and 1.0% of total IgG secreting cells in CD5+ and CD5− B cell subsets, respectively. IgM anti-TT antibody secreting cells also constitute 0.9% of total IgM pro-
producing cells of the CD5− B cell subset in SLE patients. These average values are similar to those previously reported for lupus-prone mice (12), in which the proportion of B cells producing anti-DNA antibody, as a percentage of total Ig secreting cells, was 0.76% to 1.81% in various lupus-prone murine strains. However, in certain of our patients, anti-DNA antibody secreting cells constituted more than 5% of total Ig secreting cells (Fig. 5).

When individual patients were analyzed with respect to their cellular source of anti-ssDNA antibodies, four patterns were discernible (Table II): (a) patients whose CD5+ and CD5− B cells both produce anti-DNA antibody, (b) patients who lack circulating anti-DNA antibody producing cells of either type, (c) patients whose CD5− but not CD5+ B cells produce anti-DNA, and (d) patients in whom CD5+ but not CD5− B cells produce anti-DNA. Although the first of these patterns was the most common (n = 7) and was associated with the highest levels of anti-DNA secreting cells, there were three patients whose CD5+ cells alone secreted anti-DNA, and another three patients whose CD5− cells alone secreted anti-DNA. These results suggest that the cellular origin of anti-DNA antibody is heterogeneous with respect to cell lineage (CD5+ vs. CD5−).

Drugs taken by SLE patients at the time of study, particularly corticosteroids, might have affected our results. However, there was no correlation between the level or the B cell source of anti-DNA and corticosteroid use in our patient cohort (Table I). Among those patients whose CD5+ and CD5− B cells both secreted anti-DNA, one was receiving 40 mg/d of prednisone at the time of study, one was receiving 15 mg/d, two patients were receiving 10 mg/d and three were receiving no corticosteroids. This suggests that these doses of prednisone did not affect the cellular pattern of anti-DNA antibody production although the possibility exists that the absolute num-

Figure 3. Spontaneous production of anti-ssDNA antibody and antitetanus toxoid (TT) antibody by SLE CD5+ B cells and CD5− B cells. Purified CD5+ or CD5− B cells from SLE patients as well as normal healthy control subjects were cultured for 18 h in wells coated with DNA or TT, and specific IgG and IgM producing cells were determined by ELISPOT assay. (a) IgM anti-ssDNA antibody production, (b) IgG anti-ssDNA antibody production, (c) IgM anti-TT antibody production, (d) IgG anti-TT antibody production. Brackets indicate mean±standard error of 15 SLE patients or 15 normal controls.
bers of anti-DNA secreting cells might have been affected by treatment. These results are consistent with our previous finding that the levels of polyclonal Ig production in SLE patients is not correlated with corticosteroid use (21).

*SAC I induction of anti-DNA antibody production from CD5+ and CD5− B cells.* To examine the production of anti-DNA antibody after a nonspecific in vitro stimulus, 2 × 10^5

<table>
<thead>
<tr>
<th>Pattern</th>
<th>n</th>
<th>CD5+ B</th>
<th>CD5− B</th>
<th>CD5+ B</th>
<th>CD5− B</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>7</td>
<td>156±70</td>
<td>217±113</td>
<td>104±47</td>
<td>115±34</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>&lt;20</td>
<td>&lt;20</td>
<td>&lt;20</td>
<td>&lt;20</td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>&lt;20</td>
<td>38±23</td>
<td>&lt;20</td>
<td>153±19</td>
</tr>
<tr>
<td>4</td>
<td>3</td>
<td>41±19</td>
<td>&lt;20</td>
<td>40±33</td>
<td>&lt;20</td>
</tr>
</tbody>
</table>

Four cellular patterns of anti-ssDNA antibody production by SLE patients; pattern 1 (n = 7), both CD5+ and CD5− B cells secrete IgM and/or IgG anti-ssDNA antibody; pattern 2 (n = 2), neither subpopulation secretes anti-ssDNA antibody; pattern 3 (n = 3), CD5− B cells alone secrete IgM and/or IgG anti-ssDNA antibody; pattern 4 (n = 3), CD5+ B cells alone secrete IgM and/or IgG anti-ssDNA antibody. Each value represents the mean±SE of spots/10^6 B cells of each patient group.

CD5+ or CD5− B cells from SLE patients or healthy controls were stimulated with 0.002% SAC I in the presence of normal T cell–derived helper factors, cultured for 6 d, and then assayed for production of polyclonal Ig and anti-ssDNA antibody. As shown in Fig. 6, CD5+ as well as CD5− B cells from

![Figure 4](https://doi.org/10.1172/JCI114418)

**Figure 4.** Spontaneous production of anti-double stranded (ds) DNA antibody from SLE and normal CD5+ and CD5− B cells. Spontaneous anti-dsDNA antibody production was measured by ELIspot assay as described in Methods. Each value represents the mean number of spots/10^6 B cells. Brackets indicate mean±standard error of six SLE patients or six normal control individuals.

![Figure 5](https://doi.org/10.1172/JCI114418)

**Figure 5.** Relationship between the number of specific antibody producing and total Ig producing B cells in SLE patients. The number of spontaneous IgM or IgG anti-ssDNA or IgM anti-TT antibody-secreting cells and the total number of IgM- or IgG-secreting cells were determined as described in Methods for CD5+ and CD5− B cells from 15 SLE patients. The percentage of B cells producing IgM specific for ssDNA (IgM anti-DNA), for example, was calculated by the following equation: number of IgM anti-DNA producing cells/number of IgM-producing cells ×100. Bar indicates the mean percentage of 15 SLE patients.

![Figure 6](https://doi.org/10.1172/JCI114418)

**Figure 6.** Induction of anti-DNA and anti-TT antibody production by *Staphylococcus aureus* Cowan I in combination with T cell helper factors. CD5+ and CD5− B cells from either SLE patients or normal controls were stimulated with 0.002% of *Staphylococcus aureus* Cowan I in the presence of 40% vol/vol normal T cell–derived helper factors, cultured for 6 d, and assayed for polyclonal Ig production, anti-ssDNA antibody production and anti-TT antibody production. Each value represents the number of spots/10^6 B cells.
both SLE patients and healthy control subjects produced IgM anti-DNA antibody upon stimulation with SAC I, IgG anti-DNA antibody was produced only by the B cells of SLE patients. These results further support the notion that in human SLE both types of B cells produce anti-DNA antibody.

Relationship of spontaneous anti-DNA antibody production and polyclonal Ig production in SLE CD5+ and CD5− B cell subpopulations. In order to more directly examine the possible role of polyclonal B cell activation in the production of anti-DNA antibody in SLE, we next examined the relationship between spontaneous polyclonal Ig production and spontaneous anti-ssDNA antibody production for each B cell subpopulation. As shown in Fig. 7, a and c, anti-DNA antibody production by CD5+ B cells occurred independently of polyclonal Ig production. Thus, some patients had very few anti-DNA-secreting CD5+ B cells despite large numbers of total (polyclonal) Ig secreting CD5+ B cells, whereas other patients with large numbers of anti-DNA producing CD5+ B cells had a relatively low number of polyclonal Ig secreting CD5+ B cells. This suggests that activation of anti-DNA antibody secreting CD5+ clones, in vivo, does not necessarily depend on polyclonal stimuli. In contrast to these findings, examination of the Ig secretion pattern of CD5− B cells reveals a strong correlation between polyclonal Ig production and anti-DNA antibody production (Fig. 7, b and d), suggesting that anti-DNA antibody producing clones within the CD5− subpopulation were activated, in vivo, by polyclonal stimuli.

IgM anti-TT antibody production by CD5− B cells was also associated with polyclonal IgM production by the same cells (Fig. 7 e). IgG anti-TT antibody was not associated with polyclonal IgG production; however, IgG anti-TT antibody was produced in very low frequency by only two patients (Fig. 7 f).

Discussion

In this study, a sensitive ELISpot assay was used to determine if the circulating B cells of patients with SLE spontaneously secrete anti-DNA antibody and, if so, whether CD5+ or CD5− B cells were the source of the antibody. Although there was substantial variation between patients, we found that CD5+ and/or CD5− B cells from the majority of SLE patients secreted both anti-ssDNA and anti-dsDNA antibody. In contrast, identically prepared B cell subpopulations from healthy subjects failed, with one exception, to secrete any detectable anti-DNA antibody.

CD5+ B cells have been reported previously to be a source of autoantibody production in mice as well as humans (17, 27, 28, 32, 33). In addition, CD5+ B cells are the predominant source of anti-DNA antibody in murine models of SLE (17, 18). Therefore, our finding that CD5+ B cells from SLE patients secrete anti-DNA is not necessarily surprising and suggests, for the first time, that CD5+ B cells in SLE patients can spontaneously secrete autoantibody. However, in mice CD5+ B cells produce mainly IgM antibodies whereas in this study human CD5+ B cells produced IgG as well as IgM antibodies. Moreover, in our SLE cohort there were more IgG than IgM antibody secreting CD5+ B cells (see Fig. 2). Casali et al. observed that normal human CD5+ B cells secreted IgG antibody to ssDNA upon activation with Epstein-Barr virus (28). Thus, while we do not yet know if CD5+ B cells secrete all IgG subclasses, it is clear that human CD5+ B cells can secrete IgG antibody, and this feature may distinguish human from mouse CD5+ B cells.

In contrast to CD5+ B cells, CD5− B cells have not been reported previously to produce anti-DNA or, to our knowledge, any other autoantibody. On this basis, our findings in human SLE appear to differ with previous findings in lupus prone mice (17, 18). The differences may reflect the lymphocyte sources examined; peripheral blood was analyzed in the present study, whereas spleen cells have been the major cell source studied in lupus mice. Alternatively, the mechanism responsible for anti-DNA production in human SLE may differ from that in murine models of SLE. Since humans are genetically heterogeneous, in contrast to the inbred mouse strains that develop lupus-like disease, the possibility exists that the pathogenesis of human SLE is also heterogeneous and...
varies among patients with otherwise similar clinical syndromes. Regardless of the precise explanation, the results rule out the notion that CD5+ B cells are the sole source of anti-DNA antibody in human SLE.

These results not only suggest the existence of two anti-DNA antibody producing B cell subsets in SLE but also raise the possibility that these subsets have different induction mechanisms. Thus, the levels of anti-DNA antibody secretion by CD5− B cells correlated closely with the level of polyclonal Ig production by the same subpopulation. In contrast, anti-DNA production by CD5+ B cells was independent of polyclonal Ig secretion by either this subpopulation or CD5− B cells (Fig. 7, a and c and data not shown). We interpret these findings to suggest that a polyclonal stimulus is responsible for the production of anti-DNA antibody by CD5− B cells, whereas a more selective stimulus is responsible for anti-DNA production by CD5+ B cells. Although a recent study of CD5+ B cells in NZB/NZW F1 mice has suggested that these cells may be subject to antigen-induced clonal selection (47), the stimulus responsible for the preferential activation of anti-DNA secreting CD5+ B cells in human SLE is unknown. If the repertoire of CD5+ B cells is highly restricted, the same polyclonal stimulus could conceivably be responsible for the activation of CD5+ as well as CD5− B cells.

The underlying stimulus responsible for autoantibody production in SLE has been debated for many years. One model to account for autoantibody generation suggests that self-specific antibodies are encoded by germ line V gene repertoire (48) and are thus present in both normal and diseased individuals. In normal individuals, self-reactive cells are suppressed, but in disease, an abnormal polyclonal B cell activation may occur resulting in the pathological secretion of autoantibodies (24, 49–51). This model predicts that autoantibodies would resemble those derived after polyclonal activation of normal B cells. A second model invokes self-antigens, not polyclonal activation, as the driving force for the production of autoantibodies (14, 52–54). This antigen driven model predicts that autoantibodies would resemble antibodies produced during the secondary immune response to foreign antigens; these are usually derived from clonally related precursors, somatically mutated (often reflecting selection of mutations by antigens), and isotype switched (55, 56).

It is possible that both antigen specific and polyclonal B cell activation contribute independently to the hypergammaglobulinemia and autoantibody production found in SLE patients. Alternatively, the presence of a factor capable of inducing polyclonal B cell activation in conjunction with low levels of antigen (or autoantigen) could induce the preferential proliferation of B cells reactive with that antigen. The current study suggests that polyclonal activation of B cells and preferential activation of autoantibody producing clones are not mutually exclusive; rather, both mechanisms may contribute to the formation of anti-DNA antibody in SLE patients. A similar combined model of autoimmune was proposed recently by Dziarski and Klinman et al. (57, 58).

Recent studies suggest that autoantibodies, such as rheumatoid factor and anti-DNA antibody, differ from one another in their affinity for antigen depending on the Ig V genes that encode them. Some rheumatoid factors, for example, are cross-reactive low affinity autoantibodies encoded by germ line V genes (32, 57), while others are of high affinity, harbor numerous somatic mutations and resemble antibodies elicited by exogenous antigens after secondary immunization (59–61).

In this regard, it will be of interest to determine whether the anti-DNA antibodies produced by CD5+ and CD5− B cells differ in affinity and/or V gene usage. Of course, it will be of no less importance to determine the possible contribution of anti-DNA antibody produced by CD5+ and CD5− B cells to the clinical manifestation of SLE.

Acknowledgments

The authors gratefully acknowledge the assistance of Claudia Benike, who provided helpful discussion, and Donna Jones, who provided superb secretarial support.

This work was supported, in part, by grant CA-24607 from the National Institutes of Health.

References


Cellular Source of Anti-DNA Antibody in Systemic Lupus Erythematosus 245


